IRIX Pharmaceuticals: Patheon snags another CMO amid its global expansion
Contract drug developer Patheon, a year removed from a $2.6 billion merger, is expanding its manufacturing footprint with another acquisition, buying up a South Carolina specialist.
Read full article »
Co-Founder & CEO
Guy J. Steenrod
IRIX engaged in the generation of process technology for new and existing drugs & production of Active Pharmaceutical Ingredients.
Read more